Hypofractionated Radiotherapy for Recurrent DIPG

Recurrent Diffuse Intrinsic Pontine Glioma Clinical Trial

Official title:
Feasibility Study of Hypofractionated Radiotherapy in the Setting of Recurrent Diffuse Intrinsic Pontine Glioma

Status Completed

Clinical Trial Summary

This study evaluates the feasibility of hypofractionated radiotherapy (RT) in the palliative treatment of recurrent diffuse intrinsic pontine glioma (DIPG). Participants will receive 15 Gy in 3 fractions as opposed to the standard 20 Gy in 10 fractions.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Diffuse Intrinsic Pontine Glioma
Glioma
Recurrence
Recurrent Diffuse Intrinsic Pontine Glioma

Clinical Trial Details

NCT number	NCT03841435
Study type	Interventional
Source	University of Cincinnati
Contact
Status	Completed
Phase	N/A
Start date	January 31, 2018
Completion date	March 3, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05009992` - Combination Therapy for the Treatment of Diffuse Midline Gliomas	Phase 2
Recruiting	`NCT03598244` - Volitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors	Phase 1
Recruiting	`NCT05278208` - Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors	Phase 1/Phase 2
Recruiting	`NCT02359565` - Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma	Phase 1
Recruiting	`NCT04870944` - CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma	Phase 1/Phase 2
Completed	`NCT03387020` - Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain Tumors	Phase 1